Description: Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Home Page: www.arovella.com
Corporate One
Preston,
VIC
3072
Australia
Phone:
61 3 9863 6472
Officers
| Name | Title |
|---|---|
| Dr. Michael Baker | CEO, MD & Director |
| Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. | Chief Operating Officer |
| Mr. Timothy Luscombe B.Com., C.A. | Company Secretary & CFO |
| Michelle Long | Administration Manager |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.7951 |
| Price-to-Sales TTM: | 63.0772 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |